clinical trial · NCT07354711
A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
3H Pharmaceuticals Co., Ltd.·phase2·recruiting·n = 170
Lung CancerStomach Cancer3H-10000
brief summary
The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3H-10000 in the treatment of unresectable or metastatic solid tumors .
started
Jan 4, 2026
primary completion
Jan 1, 2028
completion
Jan 1, 2029
last updated
Jan 21, 2026
official title
A Phase I/II Study of 3H-10000 (an Anti-FGFR2b Antibody-Drug Conjugate) in Subjects With Unresectable or Metastatic Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol